Emergent transcatheter mitral valve-in-valve implantation may serve as a viable therapeutic option for critically ill patients presenting with cardiogenic shock due to a failed bioprosthesis.
May serve as rescue therapy in select shock cases; leaves open need for prospective validation before broader use.
Transcatheter valve-in-valve (VIV) implantation is emerging as a therapeutic option for treatment of failed bioprosthesis in patients that are deemed high-risk or inoperable for redo-valve replacement. It can be carried out in suitable bioprosthetic valves in any position and usually performed as an elective or semi-elective procedure. Here, we report a case of emergent transcatheter VIV implantation in a failed mitral bioprosthesis in a critically ill patient with cardiogenic shock. We conclude that transcatheter VIV implantation may also be an option for critically ill patients with failing bioprosthesis.
No takes yet. Share an insight, caveat, or question.
Alli et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: